I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption ...

Given this risk, we thought we'd take a look at whether 10x Genomics (NASDAQ:TXG) shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative ...

Here are three reasons why there are better opportunities than TXG and a stock we'd rather own. Founded in 2012, 10x Genomics (NASDAQ:TXG) develops single-cell and spatial genomics solutions ...

Charles Schwab Investment Management Inc. lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 17.2% in the 4th quarter, according to the company in its most recent filing with ...

Shares of NASDAQ:TXG opened at $9.41 on Friday. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -6.19 and a beta of 1.93. 10x Genomics, Inc. has a 12 month low of $9.27 ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa ...

Flyme OS is alive and Meizu is back! The maker returns to MWC with three global smartphones - Note 22, mblu 22, mblu 22 Pro. These three run on Android 15 with Flyme skin. Meizu Note 22 is an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...